Physician profile
Edwin A Smith
NPI 1003828179
$1,109.38
in general payments reported to CMS, 2019-2025
20 companies · $86.26 in 2025
The $86.26 reported for 2025 was less than what a typical Pediatric Urology provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.15 · 2021: $34.24 · 2022: $437 · 2023: $215 · 2024: $311 · 2025: $86.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $293.73 | 2022-2024 | Tria Firm |
| Teleflex LLC | $164.00 | 2024 | Deflux |
| Bayer Healthcare Pharmaceuticals INC. | $108.98 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $76.79 | 2021-2022 | |
| Novo Nordisk INC | $68.96 | 2024 | |
| Axonics, INC. | $57.35 | 2022-2023 | Bulkamid |
| Angiodynamics, INC. | $46.89 | 2022 | |
| Bracco Diagnostics INC. | $43.24 | 2025 | |
| Merck Sharp & Dohme LLC | $42.40 | 2022 | |
| Janssen Biotech, INC. | $28.77 | 2023 | Erleada |
| Coloplast Corp | $26.55 | 2023 | Speedicath |
| Novartis Pharmaceuticals Corporation | $24.84 | 2019 | |
| Myovant Sciences INC. | $24.67 | 2022 | |
| Progenics Pharmaceuticals, INC. | $21.66 | 2025 | |
| Dendreon Pharmaceuticals LLC | $21.13 | 2024 | Provenge |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.58 | 2023 | Orgovyx |
| Blue Earth Diagnostics | $18.31 | 2023 | |
| Ambu INC. | $16.40 | 2023 | |
| Travere Therapeutics, INC. | $5.13 | 2019-2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.